Soligenix Advances Novel Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Inc. (NASDAQ: SNGX) is advancing a novel therapeutic approach for cutaneous T-cell lymphoma (CTCL) through its development of HyBryte™, also known as synthetic hypericin. CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages, creating significant challenges within the diagnostic and treatment landscape. HyBryte is a visible light-activated photodynamic therapy designed specifically for the treatment of early-stage CTCL, representing a potential advancement in addressing critical gaps in rare disease treatment.

Unlike traditional ultraviolet-based phototherapies, which can carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum. This mechanism allows for targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue. Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, with regulatory approvals being sought worldwide following successful completion of the second Phase 3 study.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's development programs also include expansion of synthetic hypericin into psoriasis, as well as its first-in-class innate defense regulator technology, dusquetide, for the treatment of inflammatory diseases including oral mucositis in head and neck cancer. Additional information about the company's research and development efforts can be found at https://www.Soligenix.com.

The development of HyBryte addresses a significant medical need in the CTCL treatment landscape, where early-stage diagnosis remains challenging and existing therapies may pose safety concerns. The visible light activation mechanism represents a departure from conventional approaches, potentially offering improved safety profiles for patients requiring ongoing treatment. As Soligenix progresses toward potential commercialization, the therapy could provide clinicians with a new option for managing this difficult-to-treat condition. The latest news and updates relating to Soligenix are available through various investment news platforms that cover developments in the biopharmaceutical sector.